Earnings Summary

10x Genomics Inc’s revenue jumped 17.76% since last year same period to $183.98Mn in the Q4 2023. On a quarterly growth basis, 10x Genomics Inc has generated 19.74% jump in its revenue since last 3-months.

10x Genomics Inc’s net profit fell -184.36% since last year same period to $-48.95Mn in the Q4 2023. On a quarterly growth basis, 10x Genomics Inc has generated 47.36% jump in its net profits since last 3-months.

10x Genomics Inc’s net profit margin fell -141.47% since last year same period to -26.61% in the Q4 2023. On a quarterly growth basis, 10x Genomics Inc has generated 56.04% jump in its net profit margins since last 3-months.

10x Genomics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.5 - a -38.89% fall from last quarter’s estimates.

10x Genomics Inc’s earning per share (EPS) estimates for the current year stand at -0.5.

10x Genomics Inc’s earning per share (EPS) fell -173.33% since last year same period to -0.41 in the Q4 2023. This indicates that the 10x Genomics Inc has generated -173.33% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. 10x Genomics Inc’s return on assets (ROA) stands at -0.12.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. 10x Genomics Inc’s return on equity (ROE) stands at -0.33.